<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291745</url>
  </required_header>
  <id_info>
    <org_study_id>O-MDS-PROTOCOL</org_study_id>
    <nct_id>NCT01291745</nct_id>
  </id_info>
  <brief_title>Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES</brief_title>
  <acronym>O-MDS-Protocol</acronym>
  <official_title>Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Amelia Scorza Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Amelia Scorza Onlus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to determine the mutational status of markers (TET2 and PLCb2,
      cytogenetic aberrations) together with methylation status of the above genes using bone
      marrow and matched buccal cell samples from MDS patients who necessitate to start a treatment
      (i.e. EPO, Lenalidomide, Azacytidine). All patients included in the study will be followed
      for at least 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analyze the incidence of TET2 gene mutations and Validation of the prognostic potential of TET2 mutations and MPLA screening</measure>
    <time_frame>2 years</time_frame>
    <description>Analyze the incidence of TET2 gene mutations in a series of MDS patients and describe the clinical status of patients carrying mutations
Validation of the prognostic potential of TET2 mutations and MPLA screening on:
Response rate to treatment with Epo, Lenalidomide and Azacitidine
Progression Free Survival (PFS )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of the prognostic potential of TET2 mutations</measure>
    <time_frame>2 years</time_frame>
    <description>Validation of the prognostic potential of Tet2 mutations on:
Overall Survival;
Validation of MLPA analyisis in the identification of cytogenetic abnormalities in MDS patients as a complementary screening tool;
Validation of the prognostic relevance of MLPA analysis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with MYELODYSPLASTIC SYNDROMES</arm_group_label>
    <description>Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bone marrow and buccal cell samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with MDS detected by current diagnostic techniques (i.e., peripheral
        blood cytopenia, bone marrow morphology, cytogenetics andFISH analysis).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Patients diagnosed with MDS according to FAB, WHO and IPSS classifications

          -  All clinically treatable MDS patients with EPO or Lenalidomide or 5-Azacytidine;

          -  Hb &lt; 10 g/dL

          -  Age ≥ 18 years

          -  Gender: Male or Female

          -  Sufficient amount of biological samples for molecular studies

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Patients who do not require treatment on &quot;watch and wait&quot; strategy

          -  Insufficient amount of biological samples for molecular studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fortunato Morabito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unità Operativa Complessa di Ematologia- Azienda Ospedaliera di Cosenza - Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fortunato Morabito, MD</last_name>
    <phone>+390984681329</phone>
    <email>omdsprotocol@fondazioneameliascorza.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna G Recchia, PhD</last_name>
    <phone>+390984681539</phone>
    <email>omdsprotocol@fondazioneameliascorza.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O. Medicina Interna Universitaria 2 ed Ematologia Ospedale Civile San Salvatore</name>
      <address>
        <city>Coppito</city>
        <state>L'Aquila</state>
        <zip>67010</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Lucchesi, MD</last_name>
      <phone>+390862368589</phone>
      <email>ale.lucchesi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alessandro Lucchesi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Ematologia e Trapianto di Midollo Osseo, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pellegrino Musto, MD</last_name>
      <phone>+390972726225</phone>
      <email>p.musto@crob.it</email>
    </contact>
    <investigator>
      <last_name>Pellegrino Musto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U. O. C. Ematologia - Azienda Ospedaliera Sant'Andrea</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria A Aloe Spiriti, MD</last_name>
      <phone>+390633775052</phone>
      <email>aloespiritisapienza@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria A Aloe Spiriti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Rossi, MD</last_name>
      <phone>+390303996573</phone>
      <email>ematologia@spedalicivili.brescia.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Rossi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Presidio Ospedaliero &quot;A. Perrino&quot;</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Quarta, MD</last_name>
      <phone>+390831537507</phone>
      <email>quarta.gianni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giovanni Quarta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Clinicizzata di Ematologia con Trapianto di Midollo Osseo. Ospedale Ferrarotto. Azienda Policlinico</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Palumbo, MD</last_name>
      <email>ga.palumbo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Palumbo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.O.C. Ematologia Azienda Ospedaliera di Catanzaro&quot;Pugliese-Ciaccio&quot;</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domenico Magro, MD</last_name>
      <phone>+390961883120</phone>
      <email>magro.dom@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Domenico Magro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia- Azienda Ospedaliera di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fortunato Morabito, MD</last_name>
      <phone>+390984681329</phone>
      <email>omdsprotocol@fondazioneameliascorza.it</email>
    </contact>
    <investigator>
      <last_name>Fortunato Morabito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Ematologia, Ospedale Madonna delle Grazie, ASM</name>
      <address>
        <city>Matera</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Fragasso, MD</last_name>
      <email>alberto.fragasso@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Fragasso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia, Oncoematologia e Unità Trapianto di Midollo Osseo, 'La Maddalena'</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Musso, MD</last_name>
      <phone>+390916806814</phone>
      <email>mamusso@libero.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Musso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Petrini, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sara Galimberti, MD</last_name>
      <email>s.galimberti@med.unipi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Sara Galimberti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Azienda Ospedaliera &quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Oliva, MD</last_name>
      <email>estheroliva@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Esther Oliva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuliana Alimena, MD</last_name>
      <email>alimena@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Giuliana Alimena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Ematologia - Policlinico Agostino Gemelli-</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria T Voso, MD</last_name>
      <phone>0630154278</phone>
      <phone_ext>0039</phone_ext>
      <email>mtvoso@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Maria T Voso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.</citation>
    <PMID>19420352</PMID>
  </reference>
  <reference>
    <citation>Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol. 2010 Jul;89(7):643-52. doi: 10.1007/s00277-010-0920-6. Epub 2010 Mar 2. Review.</citation>
    <PMID>20195608</PMID>
  </reference>
  <reference>
    <citation>Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189-99.</citation>
    <PMID>6952920</PMID>
  </reference>
  <reference>
    <citation>Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005 Feb 10;352(6):536-8.</citation>
    <PMID>15703418</PMID>
  </reference>
  <reference>
    <citation>Couronné L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, Dastugue N, Mugneret F, Lafage M, Gachard N, Nadal N, Bernard OA, Nguyen-Khac F. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia. 2010 Jan;24(1):201-3. doi: 10.1038/leu.2009.169. Epub 2009 Aug 27.</citation>
    <PMID>19710701</PMID>
  </reference>
  <reference>
    <citation>Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88. Erratum in: Blood 1998 Feb 1;91(3):1100.</citation>
    <PMID>9058730</PMID>
  </reference>
  <reference>
    <citation>Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999 Dec;10(12):1419-32.</citation>
    <PMID>10643532</PMID>
  </reference>
  <reference>
    <citation>Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7.</citation>
    <PMID>19666869</PMID>
  </reference>
  <reference>
    <citation>Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009 Jul;41(7):838-42. doi: 10.1038/ng.391. Epub 2009 May 31.</citation>
    <PMID>19483684</PMID>
  </reference>
  <reference>
    <citation>Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003 Mar;17(3):637-41.</citation>
    <PMID>12646957</PMID>
  </reference>
  <reference>
    <citation>Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007 Apr 15;109(8):1536-42.</citation>
    <PMID>17345612</PMID>
  </reference>
  <reference>
    <citation>Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control. 2008 Oct;15 Suppl:4-13. Review.</citation>
    <PMID>18813205</PMID>
  </reference>
  <reference>
    <citation>Nie HH, H.H., Jenkins JG, Steinmrenner K, Bent DH., SPSS (Statistical Package for the Social Science). 1979, New York, NY: McGraw-Hill.</citation>
  </reference>
  <reference>
    <citation>Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002 Jul 15;62(14):4075-80.</citation>
    <PMID>12124344</PMID>
  </reference>
  <reference>
    <citation>Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28.</citation>
    <PMID>18443215</PMID>
  </reference>
  <reference>
    <citation>Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998 Apr;83(4):358-68. Review.</citation>
    <PMID>9592987</PMID>
  </reference>
  <reference>
    <citation>Sekeres M, Cosgrove D, Falco A. Managing patients with low-risk MDS. Clin Adv Hematol Oncol. 2006 Jul;4(7 Suppl 16):1-10; quiz 11-2. Review.</citation>
    <PMID>17139240</PMID>
  </reference>
  <reference>
    <citation>Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.</citation>
  </reference>
  <reference>
    <citation>Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 May 15;324(5929):930-5. doi: 10.1126/science.1170116. Epub 2009 Apr 16.</citation>
    <PMID>19372391</PMID>
  </reference>
  <reference>
    <citation>Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.</citation>
    <PMID>19262601</PMID>
  </reference>
  <reference>
    <citation>Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19.</citation>
    <PMID>19295549</PMID>
  </reference>
  <reference>
    <citation>Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002 Oct 1;100(7):2292-302. Review.</citation>
    <PMID>12239137</PMID>
  </reference>
  <reference>
    <citation>Viguié F, Aboura A, Bouscary D, Ramond S, Delmer A, Tachdjian G, Marie JP, Casadevall N. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia. 2005 Aug;19(8):1411-5.</citation>
    <PMID>15920487</PMID>
  </reference>
  <reference>
    <citation>Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA, Rebbeck TR. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect. 1999 Jul;107(7):517-20.</citation>
    <PMID>10378997</PMID>
  </reference>
  <reference>
    <citation>Woo JG, Sun G, Haverbusch M, Indugula S, Martin LJ, Broderick JP, Deka R, Woo D. Quality assessment of buccal versus blood genomic DNA using the Affymetrix 500 K GeneChip. BMC Genet. 2007 Nov 8;8:79.</citation>
    <PMID>17996058</PMID>
  </reference>
  <reference>
    <citation>Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.</citation>
    <PMID>19474426</PMID>
  </reference>
  <reference>
    <citation>Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C; French Group of Familial Myeloproliferative Disorders. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009 Aug 20;114(8):1628-32. doi: 10.1182/blood-2009-01-197525. Epub 2009 Jun 29.</citation>
    <PMID>19564637</PMID>
  </reference>
  <reference>
    <citation>Schmid M. Iron chelation therapy in MDS: what have we learnt recently? Blood Rev. 2009 Dec;23 Suppl 1:S21-5. doi: 10.1016/S0268-960X(09)70006-2. Review.</citation>
    <PMID>20116636</PMID>
  </reference>
  <reference>
    <citation>Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002 Jun 15;30(12):e57.</citation>
    <PMID>12060695</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fortunato Morabito, MD</name_title>
    <organization>Unità Operativa di Ematologia- Azienda Ospedaliera di Cosenza</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

